Ocugen Files 8-K: Other Events & Financials

Ticker: OCGN · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1372299

Ocugen, INC. 8-K Filing Summary
FieldDetail
CompanyOcugen, INC. (OCGN)
Form Type8-K
Filed DateFeb 12, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, corporate-update

TL;DR

Ocugen filed an 8-K on Feb 12, 2025, covering other events and financials.

AI Summary

On February 12, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in biological products and is headquartered in Malvern, Pennsylvania.

Why It Matters

This filing provides an update on Ocugen's corporate activities and financial status, which is crucial for investors to assess the company's ongoing operations and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K report, not indicating any specific new risks or material events.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are detailed in this 8-K filing?

The provided text does not specify the 'Other Events' but indicates that 'Other Events' is an item information category for this filing.

What is the primary business of Ocugen, Inc. according to the filing?

Ocugen, Inc. is primarily involved in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code.

When was Ocugen, Inc. incorporated?

Ocugen, Inc. was incorporated in Delaware.

What is the telephone number listed for Ocugen, Inc.?

The telephone number listed for Ocugen, Inc. is (484) 328-4701.

What is the fiscal year end for Ocugen, Inc.?

The fiscal year end for Ocugen, Inc. is December 31 (1231).

Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2025-02-12 08:39:20

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. Attached as Exhibit 99.1 hereto and incorporated herein by reference is a presentation that Ocugen, Inc. will post on its website on February 12, 2025 and may use from time to time in presentations or discussions with investors, analysts, and other parties.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Document 99.1 Ocugen, Inc. Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2025 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing